TY - JOUR
T1 - Targeted therapies in the treatment of colorectal cancer
T2 - what managed care needs to know.
AU - Schwartz, Rowena N.
AU - Blanke, Charles D.
AU - Pesko, Larry John
PY - 2004/10
Y1 - 2004/10
N2 - OBJECTIVE: This review is designed to explore the disease, its current treatment, the expanding field of antiangiogenic treatments, and the implications of these advances for the managed care patient. DATA SOURCES: This article is based, in part, on presentations given by the authors in a continuing education symposium presented during the Academy of Managed Care Pharmacy.s 16th Annual Meeting and Showcase, April 1, 2004, in San Francisco. CONCLUSIONS: Colorectal cancer (CRC) is the third most common cancer in the United States, and the second-leading non.gender-specific cause of cancer deaths. If the cancer is caught soon enough (before node involvement and metastasis occur), there is a strong chance of survival; however, only slightly more than one third of cases are detected that soon. Emerging treatments that target only the cancer cells are increasing the length of survival for those who are diagnosed at later stages of the disease.
AB - OBJECTIVE: This review is designed to explore the disease, its current treatment, the expanding field of antiangiogenic treatments, and the implications of these advances for the managed care patient. DATA SOURCES: This article is based, in part, on presentations given by the authors in a continuing education symposium presented during the Academy of Managed Care Pharmacy.s 16th Annual Meeting and Showcase, April 1, 2004, in San Francisco. CONCLUSIONS: Colorectal cancer (CRC) is the third most common cancer in the United States, and the second-leading non.gender-specific cause of cancer deaths. If the cancer is caught soon enough (before node involvement and metastasis occur), there is a strong chance of survival; however, only slightly more than one third of cases are detected that soon. Emerging treatments that target only the cancer cells are increasing the length of survival for those who are diagnosed at later stages of the disease.
UR - http://www.scopus.com/inward/record.url?scp=16544380361&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=16544380361&partnerID=8YFLogxK
M3 - Review article
C2 - 15546221
AN - SCOPUS:16544380361
SN - 1083-4087
VL - 10
SP - S2-13; quiz S14-17
JO - Journal of managed care pharmacy : JMCP
JF - Journal of managed care pharmacy : JMCP
IS - 5 Suppl B
ER -